GOLDEN MEDITECH HOLDINGS LTD., a Hong Kong-based healthcare enterprise, and MD Anderson Cancer Center announced the creation of Cellenkos Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory cellular therapies. Cellenkos, to be based in Houston, is funded with an initial investment of $10 million with warrants to purchase an additional $10 million...
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe